Characteristics of patients and grafts (grouped by rejection status and diagnoses)
| Unique patient no. . | Diagnosis . | Age/sex* . | Previous autograft . | Previous regimens† . | CD34+ cells × 106/kg‡ . | CD3+ cells × 108/kg1-153 . |
|---|---|---|---|---|---|---|
| UL 607 | ALL-REL3 | 60/M | VDAspAra, IdaAra-C, FLAG × 2, FLAG × 2 | 3.9 | 4.5 | |
| 577 | MF-AML-IF | 62/M | Hu, IFN, IdaTG × 6, IdaAra-C × 2, E Ida (all for MF), HDAC, Mi | 4.8 | 4.3 | |
| FH 14241 | AML-aplasia | 49/M | IdaAra-C × 2 → 10 weeks of aplasia + aspergillosis | 10.7 | 2.7 | |
| 14560 | AML-CR1 | 63/M | IdaAra-C × 2, HDAC | 6.5 | 2.4 | |
| 13461 | AML-CR1 | 60/M | MCE × 2, AraC | 6.1 | 6.7 | |
| UL 646 | AML-CR1 | 36/F | IdaAra-C × 3 | 4.6 | 8.3 | |
| 627 | AML-CR1 | 58/F | IdaAra-C × 3 | 9.1 | 4.2 | |
| 636 | AML-CR1 | 56/F | IdaAra-C × 3 | 8.0 | 4.5 | |
| UL 616 | AML-CR2 | 72/M | TAD, HAM, Mi-FLAG | 3.1 | 2.4 | |
| FH 13361 | AML-CR3 | 66/M | D Ara-C × 3, D Ara-C × 2, IdaAra-C × 2 | 4.0 | 0.7 | |
| SU 1857 | AML-IF | 57/M | CMOPP/CHOP, XRT (for NHL), IdaAra-C for secondary AML | 6.9 | 3.1 | |
| FH 12914 | CLL-REL2 | 53/M | F × 6, F × 8 | 11.3 | 4.9 | |
| SU 1879 | CLL-PR2 | 59/M | FChP × 8, F × 8 | 5.5 | 2.0 | |
| FH 14587 | CLL-REF | 54/M | F × 6, CVP × 2 | 5.2 | 1.9 | |
| 14586 | CLL-REF | 53/M | F × 6 | 9.6 | 3.0 | |
| SU 2028 | CLL-PR2 | 55/M | CHOP × 6, CyE + Rituxin × 4 | 5.1 | 2.6 | |
| FH 14322 | CLL-REF | 46/M | Ch, CVP × 4, F × 4, CED | 10.8 | 3.9 | |
| 14627 | CLL-REF | 54/F | F × 6, CHOP × 4, CVP × 4 | 5.0 | 3.4 | |
| UL 596 | CML-AP | 64/M | Hu/IFN, Hu/TG | 4.7 | 4.3 | |
| UL 605 | CML-CP | 49/F | Hu/IFN, TG | 10.2 | 2.9 | |
| FH 14214 | CML-CP | 70/M | Hu | 3.3 | 1.7 | |
| UL 634 | CML-CP | 60/M | Hu, IdaAra-C, Hu/IFN | 5.9 | 2.5 | |
| FH 14726 | CML-CP | 61/F | Hu, IFN | 6.4 | 4.1 | |
| SU 1955 | HD-CR2 | 61/F | ABVD × 6, CHAD × 3 | 8.6 | 4.6 | |
| FH 13817 | HD-PR | 49/F | XRT, MOPP × 3, ABVD × 6, DHAP × 3, MOPP × 2 | 16.1 | 4.8 | |
| 14226 | HD-REF | 31/M | Yes | ABVD × 6, mantle XRT, MOPP × 3, HDT, Vb, GcCp × 2, Gc | 12.3 | 3.6 |
| 14692 | HD-REF | 39/M | Yes | MOPP/ABVD × 6, ABVD × 5, DHAP × 2, HDT | 4.7 | 2.4 |
| 13527 | MM-PR | 56/M | Yes | MP, VAD × 3, CyTx, HDT | 3.3 | 2.6 |
| 13922 | MM-PR | 58/F | Yes | VAD × 4, CyTx, HDT | 7.2 | 0.8 |
| 11924 | MM-PR | 44/F | Yes | VAD × 4, CyTx, HDT | 17.5 | 5.2 |
| 13541 | MM-REF | 55/F | Yes | VAD × 4, CyTx, HDT | 12.4 | 4.0 |
| 14274 | MM-REF | 63/M | Yes | VAD × 7, CyTx, HDT | 15.5 | 6.0 |
| UL 625 | MM-REF | 59/M | MP, Brendamustine + P | 9.7 | 2.9 | |
| FH 14224 | NHL-REF | 53/F | Ch, FMD × 3, Promace-Cytabom × 4, Rituxin × 4, CE × 2 | 6.0 | 7.2 | |
| 14413 | WM-REF | 50/M | F × 7, Rituxin × 4, Dex × 10 | 10.5 | 2.6 | |
| 14658 | WM-REF | 58/M | 2-CDA × 2, CVP × 2 | 13.2 | 4.9 | |
| UL 644 | AML-CR1 | 52/F | IdaAra-C × 3 | 3.8 | 3.5 | |
| 14284 | CLL-PR | 67/M | Ch, F × 3 | 6.5 | 4.3 | |
| 14091 | CML-AP | 54/M | Hu/INF, 2-CDA | 15.1 | 2.0 | |
| SU 2000 | CML-AP | 40/M | Hu | 7.7 | 4.5 | |
| SU 1948 | CML-CP | 71/M | Hu/INF, Ara-C/Hh, Ara-C | 12.7 | 3.3 | |
| UL 622 | CML-CP | 58/M | Hu | 10.8 | 3.7 | |
| FH 13009 | MDS-RAEB-T | 43/M | None | 4.4 | 2.7 | |
| 13246 | MM-REF | 58/F | VAD × 4 | 9.1 | 1.0 | |
| 13230 | MM-PR | 53/M | VAD × 7 | 10.0 | 3.3 |
| Unique patient no. . | Diagnosis . | Age/sex* . | Previous autograft . | Previous regimens† . | CD34+ cells × 106/kg‡ . | CD3+ cells × 108/kg1-153 . |
|---|---|---|---|---|---|---|
| UL 607 | ALL-REL3 | 60/M | VDAspAra, IdaAra-C, FLAG × 2, FLAG × 2 | 3.9 | 4.5 | |
| 577 | MF-AML-IF | 62/M | Hu, IFN, IdaTG × 6, IdaAra-C × 2, E Ida (all for MF), HDAC, Mi | 4.8 | 4.3 | |
| FH 14241 | AML-aplasia | 49/M | IdaAra-C × 2 → 10 weeks of aplasia + aspergillosis | 10.7 | 2.7 | |
| 14560 | AML-CR1 | 63/M | IdaAra-C × 2, HDAC | 6.5 | 2.4 | |
| 13461 | AML-CR1 | 60/M | MCE × 2, AraC | 6.1 | 6.7 | |
| UL 646 | AML-CR1 | 36/F | IdaAra-C × 3 | 4.6 | 8.3 | |
| 627 | AML-CR1 | 58/F | IdaAra-C × 3 | 9.1 | 4.2 | |
| 636 | AML-CR1 | 56/F | IdaAra-C × 3 | 8.0 | 4.5 | |
| UL 616 | AML-CR2 | 72/M | TAD, HAM, Mi-FLAG | 3.1 | 2.4 | |
| FH 13361 | AML-CR3 | 66/M | D Ara-C × 3, D Ara-C × 2, IdaAra-C × 2 | 4.0 | 0.7 | |
| SU 1857 | AML-IF | 57/M | CMOPP/CHOP, XRT (for NHL), IdaAra-C for secondary AML | 6.9 | 3.1 | |
| FH 12914 | CLL-REL2 | 53/M | F × 6, F × 8 | 11.3 | 4.9 | |
| SU 1879 | CLL-PR2 | 59/M | FChP × 8, F × 8 | 5.5 | 2.0 | |
| FH 14587 | CLL-REF | 54/M | F × 6, CVP × 2 | 5.2 | 1.9 | |
| 14586 | CLL-REF | 53/M | F × 6 | 9.6 | 3.0 | |
| SU 2028 | CLL-PR2 | 55/M | CHOP × 6, CyE + Rituxin × 4 | 5.1 | 2.6 | |
| FH 14322 | CLL-REF | 46/M | Ch, CVP × 4, F × 4, CED | 10.8 | 3.9 | |
| 14627 | CLL-REF | 54/F | F × 6, CHOP × 4, CVP × 4 | 5.0 | 3.4 | |
| UL 596 | CML-AP | 64/M | Hu/IFN, Hu/TG | 4.7 | 4.3 | |
| UL 605 | CML-CP | 49/F | Hu/IFN, TG | 10.2 | 2.9 | |
| FH 14214 | CML-CP | 70/M | Hu | 3.3 | 1.7 | |
| UL 634 | CML-CP | 60/M | Hu, IdaAra-C, Hu/IFN | 5.9 | 2.5 | |
| FH 14726 | CML-CP | 61/F | Hu, IFN | 6.4 | 4.1 | |
| SU 1955 | HD-CR2 | 61/F | ABVD × 6, CHAD × 3 | 8.6 | 4.6 | |
| FH 13817 | HD-PR | 49/F | XRT, MOPP × 3, ABVD × 6, DHAP × 3, MOPP × 2 | 16.1 | 4.8 | |
| 14226 | HD-REF | 31/M | Yes | ABVD × 6, mantle XRT, MOPP × 3, HDT, Vb, GcCp × 2, Gc | 12.3 | 3.6 |
| 14692 | HD-REF | 39/M | Yes | MOPP/ABVD × 6, ABVD × 5, DHAP × 2, HDT | 4.7 | 2.4 |
| 13527 | MM-PR | 56/M | Yes | MP, VAD × 3, CyTx, HDT | 3.3 | 2.6 |
| 13922 | MM-PR | 58/F | Yes | VAD × 4, CyTx, HDT | 7.2 | 0.8 |
| 11924 | MM-PR | 44/F | Yes | VAD × 4, CyTx, HDT | 17.5 | 5.2 |
| 13541 | MM-REF | 55/F | Yes | VAD × 4, CyTx, HDT | 12.4 | 4.0 |
| 14274 | MM-REF | 63/M | Yes | VAD × 7, CyTx, HDT | 15.5 | 6.0 |
| UL 625 | MM-REF | 59/M | MP, Brendamustine + P | 9.7 | 2.9 | |
| FH 14224 | NHL-REF | 53/F | Ch, FMD × 3, Promace-Cytabom × 4, Rituxin × 4, CE × 2 | 6.0 | 7.2 | |
| 14413 | WM-REF | 50/M | F × 7, Rituxin × 4, Dex × 10 | 10.5 | 2.6 | |
| 14658 | WM-REF | 58/M | 2-CDA × 2, CVP × 2 | 13.2 | 4.9 | |
| UL 644 | AML-CR1 | 52/F | IdaAra-C × 3 | 3.8 | 3.5 | |
| 14284 | CLL-PR | 67/M | Ch, F × 3 | 6.5 | 4.3 | |
| 14091 | CML-AP | 54/M | Hu/INF, 2-CDA | 15.1 | 2.0 | |
| SU 2000 | CML-AP | 40/M | Hu | 7.7 | 4.5 | |
| SU 1948 | CML-CP | 71/M | Hu/INF, Ara-C/Hh, Ara-C | 12.7 | 3.3 | |
| UL 622 | CML-CP | 58/M | Hu | 10.8 | 3.7 | |
| FH 13009 | MDS-RAEB-T | 43/M | None | 4.4 | 2.7 | |
| 13246 | MM-REF | 58/F | VAD × 4 | 9.1 | 1.0 | |
| 13230 | MM-PR | 53/M | VAD × 7 | 10.0 | 3.3 |
UL indicates University of Leipzig; ALL, acute lymphocytic leukemia; REL, untreated relapse; MF, myelofibrosis; AML, acute myelogenous leukemia; IF, chemotherapy induction failure; FH, Fred Hutchinson Cancer Research Center; CR, complete remission; SU, Stanford University; CLL, chronic lymphocytic leukemia; PR, partial remission; REF, refractory to conventional chemotherapy; CML, chronic myelogenous leukemia; AP, accelerated phase; CP, chronic phase; HD, Hodgkin disease; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; WM, Waldenström macroglobulinemia; MDS, myelodysplastic syndrome; RAEB-T, refractory anemia with excess blasts in transformation.
Median age = 56 years.
Previous regimens: eg, ×2 = 2 cycles. Abbreviations are expanded in the at the end this article.
Median CD34+ cell dose = 9 × 106/kg.
Median CD3+ cell dose = 3.3 × 108/kg.